Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 11/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064940 | 1.00 | CA12 (0.37) | CA12CA7CA14PLGPLAT | |
| SCHEMBL13450369 | 0.84 | CA12 (0.50) | CA12CA7CA14GRIA2GRIA4 | |
| SCHEMBL13565274 | 0.80 | NPY5R (0.37) | CA12CA7CA14GRIA2 | |
| SCHEMBL17090029 | 0.80 | NPY5R (0.37) | CA12CA7CA14GRIA2 | |
| SCHEMBL17507854 | 0.79 | CA12 (0.41) | CA12CA7CA14PLGPLAT | |
| SCHEMBL12017941 | 0.79 | CA12 (0.41) | CA12CA7CA14PLGPLAT | |
| SCHEMBL30327432 | 0.77 | CA12 (0.39) | CA12CA7CA14PLGPLAT | |
| SCHEMBL4377598 | 0.76 | TDP1 (0.40) | — | |
| SCHEMBL18234121 | 0.76 | CA12 (0.46) | CA12CA7CA14GRIA2GRIA4 | |
| SCHEMBL8223048 | 0.76 | CA12 (0.52) | CA12CA7CA14GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035855-A2 | NOVEL USES OF HALOGENATED ALKYL SULFONAMIDES | H. LUNDBECK A/S (DK) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008134228-A1 | BENZOXAZOLE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
| US-20070213376-A1 | Halogenated sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| WO-2007002126-A1 | ALKYL SULFONAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213376-A1 | Halogenated sulfonamide derivatives | NPY5R, NPY2R, SSTR5 | CA12 1634/4885CA7 1620/4885CA14 1925/4885 |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | NPY5R, NPY1R, NPY4R | CA12 2414/4885CA7 1714/4885CA14 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.